Q-omics provides the consensus-scored FCF1P8 profile across patient tissues and cancer cell-line models. FCF1P8 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FCF1P8 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, FCF1P8 RNA expression shows 11,042 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where FCF1P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCF1P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCF1P8 survival associations across molecular data types. FCF1P8 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCF1P8 RNA expression–survival associations across cancer types. High FCF1P8 expression shows unfavorable associations in COAD and LIHC, but favorable associations in HNSC, LUAD, BLCA and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for FCF1P8 RNA expression.
This table summarizes FCF1P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FCF1P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCF1P8 shows lower tumor expression in THCA and higher tumor expression in KIRC, BRCA, LUAD, PRAD and COAD. The KIRC box plot shows higher FCF1P8 RNA expression in tumor versus normal tissue (log2 FC = +0.038, t-test p < 0.001).
This table shows molecular features associated with FCF1P8 in patient tissues and cancer cell lines. In patient samples, FCF1P8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
